Home > Healthcare > Medical Devices > Rehabilitation and Assistive Devices > Da Vinci Systems Market
Da Vinci Systems Market size is anticipated to witness substantial growth between 2024 and 2032, driven by the rising preference for minimally invasive surgeries. Da Vinci surgical system offers myriad benefits like limited loss of blood, reduced pain, quick recovery, fewer hospital stays, less scarring, and reduced risk of infections as it employs fewer sutures and smaller incisions. The increasing government oversight for the adoption of robots in healthcare is one of the major trends augmenting the industry gains. For instance, in March 2023, the U.K. government invested £16m in AI healthcare technologies for speeding up diagnostics.
Training programs for surgeons and medical professionals has also become integral to the successful adoption of robotic surgery. Medical institutions and manufacturers are increasingly investing in educational initiatives to ensure proficiency in using the systems. Rising efforts to improve cost-effectiveness and accessibility along with the development of more compact and versatile robotic systems will also contribute to the product usage. However, despite a broad scope for adoption, the rare risk associated with the malfunction of Da Vinci systems may constrain the industry development to some degree. The surgeries performed using Da Vinci systems also boast of higher costs and longer time than conventional procedures.
The ongoing improvements in the field of robotic surgery, such as enhancements in robotic arms, imaging systems and the higher integration of AI is leading to improved precision, efficiency, and outcomes. While enhanced imaging technologies offer surgeons with high-definition and 3D views of the surgical site, enhanced visualization helps to navigate complex anatomical structures with greater clarity. The introduction of wristed instruments to mimic the natural range of motion of the human hand for allowing more precise and intricate movements within the body will also define the industry development.
The robotic systems segment is slated to witness lucrative gains through 2032. The progression can be attributed to the rising usage of robotic systems for performing gynaecological, bariatric, cardiac, head and neck, and urological surgeries. For instance, in February 2023, Global Hospitals introduced the Da Vinci Xi robotic surgical system deployed with 3D imaging technology and superior mobility to render faster recovery compared to open surgery. These systems offer robotic precision and produce better results with less trauma to the surrounding untreated tissue. They also have multiple benefits, such as reduced hospitalization, quick recovery, minimal blood loss, and others.
The urologic surgery segment is anticipated to register substantial revenue by 2032. Da Vinci systems are used for processes related to the urinary tract like cystectomy, nephrectomy, and prostatectomy for removing cancerous tissues. The growing incidence of urinary tract disorders is likely to proliferate the demand for the systems in the coming years. As per the American Cancer Society's estimates, about 83,190 new cases of bladder cancer are estimated in the U.S. in 2024.
The Asia Pacific Da Vinci systems market is expected to foresee considerable expansion from 2024-2032, due to the rising spending by government on healthcare. To cite an instance, in India's Union Budget for the year 2022-23, more than USD 11.28 billion was allocated to the Ministry of Health and Family Welfare. The growing burden of chronic ailments and the widespread adoption of robotic surgeries will also contribute to the regional industry expansion. As per the Journal of Thoracic Oncology, lung cancer is responsible for 8.1% of all cancer-related deaths in India.
Some of the major firms operating in the Da Vinci systems industry are:
Leading Da Vinci systems industry leaders are focusing on various growth-based initiatives, including product innovations, mergers, and partnerships to consolidate their industry position.
In January 2024, American robotic provider Intuitive Surgical submitted the FDA 510(k) clearance for its gen-next da Vinci 5 multiport surgical robot to expand its existing product portfolio.